Characterization of PTPN2 and its use as a biomarker - PubMed (original) (raw)

. 2014 Jan 15;65(2):239-46.

doi: 10.1016/j.ymeth.2013.08.020. Epub 2013 Aug 30.

Affiliations

Characterization of PTPN2 and its use as a biomarker

Stéphanie Bussières-Marmen et al. Methods. 2014.

Abstract

For years, the two main isoforms of PTPN2 have been an interesting yet academic topic of debate for researchers working on this phosphatase. In recent years, several studies were published in which these isoforms were attributed specific functions. Most importantly, differences in their stoichiometry have been reported to be associated with certain diseases such as inflammatory bowel diseases (IBDs). Hence, understanding the evolutionary ontogeny of the main transcripts and the physiological consequences of their expression have now become clinically relevant issues. Herein we describe the genomic controls placed upon PTPN2, the identified splice variants, the encoded PTPN2 proteins, and both the known and putative post-translational modifications that have been reported. Moreover, we examine the expression of PTPN2 isoforms in specific tissues as well as in a disease setting. PTPN2 is an important negative regulator of inflammation. Therefore, the following protocols are effective approaches for its adequate monitoring in inflammatory diseases' progression and outcome.

Keywords: Alternative splicing; Monoclonal antibodies; PTPN2 isoforms; RNA sequencing; SNP genotyping; siRNA.

Copyright © 2013 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources